7.1.6
Treatment regimens for patients previously treated for TB
National TB Management Guidelines, 2018 Edition. Chapter 7, Tuberculosis Management and Monitoring.
Clinical description
Patients eligible for retreatment should be referred for a rapid molecular test r drug susceptibility testing to determine at least rifampicin resistance, and preferably also isoniazid resistance status.
On the basics of the drug susceptibility profile, a standard first-line treatment regimen (2HRZE/4HR) can be repeated if no resistance is documented; and if rifampicin résistance is present, an MDR-TB regimen should be prescribed according to WHO’s recent drug resistant TB treatment guidelines.
Check doses against the printed guideline and your clinical judgement before treating a patient. Spotted an error? Report it from the contact links below.
Need this without data?
The app holds every guideline on your device, with calculators, bookmarks and notes.